Results 121 to 130 of about 3,831 (231)

Ex vivo characterisation of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactam

, 2018
The combination product meropenem/vaborbactam, with activity against KPC-producing carbapenem resistant Enterobacteriaceae, is likely to be used during renal replacement therapy. The aim of this work was to describe the extracorporeal removal (adsorption
Sime, Fekade B., Lipman, Jeffrey, Alexander, Elizabeth, Karamujic, Nermin, Durso, Stephanie, Griffith, David, Pandey, Saurabh, Wallis, Steven C., Parker, Suzanne, Loutit, Jeffery, Roberts, Jason A.   +10 more
core   +1 more source

Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model [PDF]

, 2020
Christian M Gill, Tomefa E. Asempa, David P. Nicolau   +2 more
openalex   +1 more source

Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae [PDF]

, 2023
Tara M Rogers, Ellen G Kline, M. Patrick Griffith, Chelsea E Jones, Abigail M Rubio, Kevin M Squires, Ryan K. Shields   +6 more
openalex   +1 more source

A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study

, 2019
A simple method for the simultaneous quantification of meropenem and the recently approved β-lactamase inhibitor, vaborbactam, in human plasma and renal replacement therapy effluent (RRTE) was developed and validated. This antibiotic combination protects
Sime, Fekade B., Lipman, Jeffrey, Parker, Suzanne L., Pandey, Saurabh, Wallis, Steven C., Roberts, Jason A.   +5 more
core   +1 more source

Η εφαρμογή του νέου αναστολέα vaborbactam στη θεραπευτική των λοιμώξεων [PDF]

, 2022
Οι λοιμώξεις από ανθεκτικά στις καρβαπενέμες Enterobacterales, Pseudomonas aeruginosa, και Acinetobacter baumannii αποτελούν απειλή για τη δημόσια υγεία παγκοσμίως, και σχετίζονται με αυξημένη νοσηρότητα και θνητότητα.
Amargianitaki Eirini, Αμαργιανιτάκη Ειρήνη   +1 more
core  

Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam

, 2020
Ruslan Tsivkovski, Olga Lomovskaya
openalex   +1 more source

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

Antibiotics
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj   +1 more source

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales

BMC Infectious Diseases
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +3 more
doaj   +1 more source

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020 [PDF]

, 2022
Federica Bovo, Donatella Lombardo, Tiziana Lazzarotto, Simone Ambretti, Paolo Gaibani   +4 more
openalex   +1 more source

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

BMC Pulmonary Medicine
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Timothy B. Doyle, Mariana Castanheira   +4 more
doaj   +1 more source